TNFRSF9 and neoplasm: Our finding that patients receiving the combination of GVAX, anti-PD1, and CD137 agonist demonstrate higher percent collagen area in their tumor tissue overall and directly surrounding lymphoid aggregates than GVAX alone or in combination with anti-PD1 is therefore unexpected given the associated improvements clinically.